Back

Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: Long-term outcomes from the PRESERVE EF study

13 April 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Ventricular arrhythmias risk stratification Clinical EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Ioannis Doundoulakis

Vrije University Brussels, Brussels (Belgium)

6 More presentations in this session

Presentation thumbnail
Machine learning-based prediction of drug-induced QTc changes in a large Finnish biobank cohort
Doctor V. Langen (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Characteristics of patients with mitral valve prolapse presenting with sudden cardiac arrest: a single-center case-control study
Doctor N. Martini (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Identifying the vulnerable: navigating the predictors of implantable cardioverter defibrillator (ICD) therapy in the moderately reduced ejection fraction (EF) cohort
Doctor M. Abdelfattah (Aswan, EG)
Abstract Slides Video
Presentation thumbnail
Effect of flecainide on complex ventricular arrhythmogenesis: insights from the prospective UNIFLECA study
Doctor M. Botis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Gender differences in risk of sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or coronary artery disease: targeted insights from the SCD-PROTECT study
Professor D. Duncker (Hannover, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular arrhythmias risk stratification

The Event

Event poster

EHRA 2026

13 April 2026 15:30 CET
You may be interested in
thumbnail
Congress Presentation
PostMI with EF>40% and NSVT (preserve VT)
thumbnail
Congress Presentation
Risk prediction for sudden cardiac death. Insights from PROFID and other projects
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources